Louis Fleur - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Louis Fleur's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Louis Fleur
Verified
Chief Editor and Blogger, Complètement Flou
Lyon
Beats
Film and Television with a focus on but not limited to genre entertainment. Independent productions welcome.
backpackers
Content
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study - The Lancet Oncology
By Louis Fleur, Rob Kessels, Ingrid A Mandjes, Inge Kemper| The Lancet Verified 1. Gianni L Pienkowski T Im YH et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016; 17: 791-8002. Broglio KR Quintana M Foster M et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. JAMA Oncol. 2016; 2: 751-7603.
By Louis Fleur| Deco.fr@ 1. La vigne vierge, un basique prolifique La vigne vierge est une plante grimpante bien connue des jardiniers pressés ; avec sa croissance rapide (elle grandit d'environ 2 à 3 mètres par saison) et son feuillage dense, elle n'a pas son pareil pour recouvrir un muret, une pergola ou un treillage en moins de temps qu'il ne faut pour le dire.
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study - The Lancet Oncology
By Louis Fleur, Rob Kessels, Ingrid A Mandjes, Inge Kemper| The Lancet Verified 1. Gianni L Pienkowski T Im YH et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016; 17: 791-8002. Broglio KR Quintana M Foster M et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. JAMA Oncol. 2016; 2: 751-7603.
Company Info
Complètement Flou
Paris, Ile-de-France, France